Real World Evidence Solutions Market: By Component (Claims Data, Clinical Data Setting, Pharmacy data, and Others), Indication (Cardiovascular Diseases, Oncology, Neurology, Urology, and Others), and Geography

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Real World Evidence Solutions Market size was valued at USD 2.2 billion in 2022 and it is expected to grow to USD 8.6 billion growing at an 8.5% CAGR from 2023 to 2029. Real-world evidence is clinically gathered data through various studies and analyses which helps pharmaceuticals, medical device companies, and healthcare providers to implement new products or services in the market. Real-world data include randomized trials, simple trials, and observational studies. The growing amount of big data in healthcare, the shift from volume to value-based care, and the rising focus on personalized healthcare are expected to positively impact the RWE solutions market. Pharmaceutical healthcare providers are ready to invest in the development of novel drugs and services, to the demand for drug discovery and development they are shifting to outsourcing data and services, to get data for early and late-stage phases. With the prevalence of increase in research & development expenditure, pharmaceuticals need preclinical and post-clinical services which drive the market for real-world evidence solutions. Although, key players started using real-world evidence solutions for randomized solutions clinical data results increase the opportunity real word evidence solutions. The lack of consensus and real-world evidence standard lacks in quality to be part of the body of evidence to determine the comparative effectiveness of different treatment options.  

Real World Evidence Solutions Market key Developments:
In August 2022, Trinity Lifesciences announced a partnership with Bain & Company. The partnership is to intend to pair extensive experience in the life sciences with the evidence-based solutions of Trinity Life Sciences.

Real World Evidence Solutions Market Summary

Study Period

2023-29

Base Year

2022

CAGR

8.5%

Largest Market

Asia Pacific

Fastest Growing Market

North America
Real World Evidence Solutions Market Dynamics

The increasing prevalence of clinical data outsourcing across the world is the major market driver in the Real-World Evidence Solutions Market during the forecast period. Outsourcing of data to gain new segment of the market through clinical trials provide information for the new research and development sector which drives the market, gaining information on a clinical trial, and other drug data to use for new research and development. Hence, this will drive global market growth at a significant rate.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018-2022), and forecast (2023-2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Real World Evidence Solutions Market Segmentation

By Component
  • Claims Data
  • Clinical Data Setting
  • Pharmacy data
  • Others
By Indication
  • Cardiovascular diseases
  • Oncology
  • Neurology
  • Urology
  • Others
By Geography
  • North America
  • Europe
  • The Asia Pacific
  • Latin America
  • MEA
LOCATION

Geography

Frequently Asked Questions

The real-world evidence solutions market size is USD 2.2 billion in 2022 and it is expected to grow to USD 8.6 billion growing at an 8.5% CAGR from 2023 to 2029.

The leading players in the Real-World Evidence Solutions Market are IQVIA, IBM, PPD Inc., Parexel International Corporation, PerkinElmer Inc., Icon Plc, Oracle, Syneos Health, Cegedim Health Data, Medpace,

Historic years considered for the market study are 2018 through 2022, 2022 is considered as the base year for market estimation and Seven years forecast is presented from 2023 – 2029.

  • IBM
  • PPD Inc
  • IQVIA
  • Medpace
  • PerkinElmer Inc.
  • Icon Plc,
  • Oracle
  • Parexel International Corporation
  • Syneos Health
  • Cegedim Health Data